February 27, 2007
RXi Pharma appoints board
By Christina Davis
Worcester-based RXi Pharmaceuticals Corp., a subsidiary of Los Angeles-based CytRx Corp., announced the formation of a five-member board.
The director appointments include: Mark Ahn, president, CEO and director of Hana Biosciences Inc.; Stephen S. Galliker, executive vice president, finance and administration, and CFO of Dyax Corp.; Sanford J. Hillsberg, managing partner of Troy & Gould Professional Corp.; Steven A. Kriegsman, director, president and CEO of CytRx; Tod Woolf, president and CEO of RXi.
RXi's initial focus is on developing RNAi-based therapeutics for the treatment of various disorders, including neurodegenerative diseases, type 2 diabetes and obesity.
The director appointments include: Mark Ahn, president, CEO and director of Hana Biosciences Inc.; Stephen S. Galliker, executive vice president, finance and administration, and CFO of Dyax Corp.; Sanford J. Hillsberg, managing partner of Troy & Gould Professional Corp.; Steven A. Kriegsman, director, president and CEO of CytRx; Tod Woolf, president and CEO of RXi.
RXi's initial focus is on developing RNAi-based therapeutics for the treatment of various disorders, including neurodegenerative diseases, type 2 diabetes and obesity.
WBJ Web Partners
Most Recent
Most Recent
0 Comments